Combination of RAD001 (everolimus) and docetaxel reduces prostate and breast cancer cell VEGF production and tumour vascularisation independently of sphingosine-kinase-1

Resistance to docetaxel is a key problem in current prostate and breast cancer management. We have recently discovered a new molecular mechanism of prostate cancer docetaxel chemoresistance mediated by the mammalian target of rapamycin (mTOR)/sphingosine-kinase-1 (SK1) pathway. Here we investigated...

Descripción completa

Detalles Bibliográficos
Autores principales: Alshaker, Heba, Wang, Qi, Böhler, Torsten, Mills, Robert, Winkler, Mathias, Arafat, Tawfiq, Kawano, Yoshiaki, Pchejetski, Dmitri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471177/
https://www.ncbi.nlm.nih.gov/pubmed/28615679
http://dx.doi.org/10.1038/s41598-017-03728-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471177/
https://www.ncbi.nlm.nih.gov/pubmed/28615679
http://dx.doi.org/10.1038/s41598-017-03728-3

Ejemplares similares